Affiliation:
1. Vishnevsky National Medical Research Center of Surgery; Peoples' Friendship University of Russia
2. Vishnevsky National Medical Research Center of Surgery
3. Pletnev City Clinical Hospital
Abstract
In recent years, the approach to the treatment of advanced renal cell carcinoma (RCC) has undergone significant changes. The introduction of targeted drugs in the systemic therapy of RCC in the 2000s began with tyrosine kinase inhibitors that replaced cytokines and had a revolutionary effect. Then the therapeutic arsenal was expanded with the introduction of doublets consisting of a combination of immune checkpoint inhibitors or immune checkpoint inhibitors and tyrosine kinase inhibitors. Tyrosine kinase inhibitors continue to represent an effective treatment option for metastatic RCC (mRCC), maintaining their position as first-line therapy in patients with a favorable prognosis. According to the CheckMate study, targeted therapy is highly effective, and the incidence of complications is generally lower than with nivolumab/ipilimumab combination therapy. Unlike dual immunotherapy, sunitinib does not expose patients with a favorable prognosis to undue risk of adverse events, while leaving more options for subsequent lines of therapy, and it's also often more cost-effective. The presented clinical observation is an example of successful monotherapy with sunitinib in a previously untreated mRCC patient with a favorable prognosis. This case is of particular interest due to the lesion of a single kidney and the patient's polymorbidity. Effective targeted therapy in the postoperative period had a positive effect on the quality and life expectancy.
Reference34 articles.
1. Kaprin A.D., Starinsky V.V., Shakhzadova A.O. (eds.). Malignant neoplasms in Russia in 2020 (morbidity and mortality). Moscow: MNIOI; 2021. 252 p. (In Russ.) Available at: https//glavonco.ru/cancer_register/Забол_2020_Электр.pdf.
2. Adashek J., Aydin A., Kim P., Spiess P. The role of metastasectomy in the treatment of metastatic renal cell carcinoma. AME Med J. 2019;(4):30-41. https://doi.org/10.21037/amj.2019.06.02.
3. Martinez-Salamanca J.I., Linares E., Gonzalez J., Bertini R., Carballido J.A., Chromecki T. et al. Lessons learned from the International Renal Cell Carcinoma-Venous Thrombus Consortium (IRCC-VTC). Curr Urol Rep. 2014;15(5):404. https://doi.org/10.1007/s11934-014-0404-7.
4. Volkova M.I., Klimov A.V., Chernyaev V.A. Palliative nephrectomy: do all patients need surgery? Malignant Tumors. 2016;(4s1):115-118. (In Russ.) Available at: https://www.malignanttumors.org/jour/article/view/299.
5. Alekseev B.Ya., Bolotina L.V., Bezhanova S.D., Volkova M.I., Govorov A.V., Gorban N.A. et al. Cancer of the parenchyma of the kidney: clinical guidelines. Moscow; 2021. 108 p. (In Russ.) Available at: https://cr.minzdrav.gov.ru/recomend/10_3.